Skip to main content

Table 1 Demographics, disease characteristics and medications.

From: Self-management skills in adolescents with chronic rheumatic disease: A cross-sectional survey

  N (%) Mean (SD)
or
Median (Range)
Gender   
   Male 11 (21%)  
   Female 41 (79%)  
Mean age (SD)#   15.9 (2.1)
   Race/Ethnicity   
   Caucasian 26 (50%)  
   Asian 12 (23%)  
   Latino 4 (8%)  
   African American 3 (6%)  
   Other/Unknown 7 (13%)  
Diagnosis   
   Juvenile Idiopathic Arthritis 23 (44%)  
Oligoarthritis 1 (2%)  
Rheumatoid factor positive polyarthritis 3 (6%)  
Rheumatoid factor negative polyarthritis 8 (15%)  
Systemic arthritis 8 (15%)  
Enthesitis-related arthritis 2 (4%)  
Psoriatic arthritis 1 (2%)  
   Systemic Lupus Erythematosus 18 (35%)  
   Juvenile Dermatomyositis 4 (8%)  
   Mixed Connective Tissue Disease 3 (6%)  
   Scleroderma 2 (4%)  
   Idiopathic Thrombocytopenic Purpura 1 (2%)  
   Periodic Fever Syndrome 1 (2%)  
Median Disease Duration (Range)#   5.3 (0-15)
Mean Self-Reported Disease Activity (SD)*   4.1 (2.6)
Medications   
   Corticosteroids 30 (58%)  
   Methotrexate or Leflunomide 24 (45%)  
   Hydroxychloroquine 19 (37%)  
   Biologic 15 (29%)  
   Immunosuppressant+ 13 (25%)  
   Intravenous Immunoglobulin 2 (4%)  
   Non-Steroidal Anti-Inflammatory Drug 2 (4%)  
  1. # Years.
  2. * Disease activity reported on a 0-10 Likert scale, with 0 meaning "Not Active" and 10 meaning "Very Active."
  3. + Immunosuppressants include cyclophosphamide, azathioprine, myophenolate mofetil, tacrolimus, and cyclosporine.